Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on May 28, 2025
Leading Global Manufacturer Requests HPQ’s First Batch of Fumed Silica for Evaluation
GlobeNewswire
·
May 28, 2025
MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform shareholders …
Un fabricant de premier plan a demandé un lot de silice pyrogénée issu du plus récent essai de HPQ, à des fins d’évaluation
GlobeNewswire
·
May 28, 2025
MONTRÉAL, 28 mai 2025 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), une entreprise technologique spécialisée dans l’innovation en matériaux avancés et dans la mise au point de procédés critiques …
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
GlobeNewswire
·
May 28, 2025
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, …
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and …
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
GlobeNewswire
·
May 28, 2025
Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTA …
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
GlobeNewswire
·
May 28, 2025
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as …
Goliath Mobilizes For Its Largest Drill Program Of 40,000 Meters With 9 Rigs On The Extensive Surebet High-Grade Gold Discovery That Remains Wide Open Golddigger Property, Golden Triangle, B.C.
GlobeNewswire
·
May 28, 2025
Goliath is embarking on its largest drill program to date that is 100% focused on the extensive Surebet high-grade gold discovery totaling 40,000 meters with 9 rigs based on the positive results from the 2024 drill season which has greatly improved the …
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
GlobeNewswire
·
May 28, 2025
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) …
Canadian North Resources Inc. Reports Operational and Financial Results for the First Quarter Ended March 31, 2025
GlobeNewswire
·
May 28, 2025
Highlights: Continued evaluation of multiple metal processing technologies to produce market-ready battery-grade nickel and cobalt compounds, copper and PGE metals from a low-cost, low-carbon footprint mine for the Ferguson Lake Ni-Cu-Co PGE Project …